胆汁酸核受体和脂肪因子在非酒精性脂肪性肝病发病中的作用*

doi:10.3969/j.issn.1672-5069.2014.01.031

Abstract

Abstract: Non-alcoholic fatty liver disease（NAFLD）is the most common chronic liver disease worldwild. Insulin resistance is among the major causes of NAFLD,but its specific pathogenesis is still unclear. Recent findings show that bile acid nuclear receptors improve insulin resistance and liver fibrosis. Furthernore,a variety of adipokines secreted by fat cells play an important roles in the onset and progression of NAFLD. In addition,studies also show that bile acid nuclear receptors can affect the secretion of adipokines.

Key words: Nonalcoholic fatty liver disease, Adipokines, Bile acid nuclear receptor

Xin Xiaomin, Zhu Wei, Zhang Yali. Bile acid nuclear receptors and adipokines in the pathogenesis of non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 95-98.

References

[1] 魏珏,叶丽静,邱德凯,等. 胆汁酸核受体FXR在非酒精性脂肪性肝病中的作用. 胃肠病学,2010,15（1）：21-24.
[2] Gariani K,Philippe J,Jornayvaz FR. Non-alcoholic fatty liver disease and insulin resistance：from bench to bedside. Diabetes Metab,2013,39（1）：16-26.
[3] Sinal CJ,Tohkin M,Miyata M,et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell,2000,102（6）：731-744.
[4] Claudel T,Inoue Y,Barbier O,et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology,2003,125（2）：544-555.
[5] Yamagata K,Daitoku H,Shimamoto Y,et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem,2004,279（22）：23158-23165.
[6] Wang YD,Chen WD,Wang M,et al. Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response. Hepatology,2008,48（5）：1632-1643.
[7] Zhang S,Wang J,Liu Q,et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol,2009,51（2）：380-388.
[8] Arita Y,Kihara S,Ouchi N,et al. Paradoxical decrease of an adipose-specific protein,adiponectin,in obesitys. Biochem Biophys Res Commun,1999,257（1）：79-83.
[9] Cnop M,Havel PJ,Utzschneider K M,et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins：evidence for independent roles of age and sex. Diabetologia,2003,46（4）：459-469.
[10] Polyzos SA,Kountouras J,Zavos C. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. Hippokratia,2009, 13（2）：127-128.
[11] Buechler C,Wanninger J,Neumeier M. Adiponectin,a key adipokine in obesity related liver diseases. World J Gastroenterol,2011,17（23）：2801-2811.
[12] Polyzos SA,Toulis KA,Goulis DG,et al. Serum total adiponectin in nonalcoholic fatty liver disease：a systematic review and meta-analysis. Metabolism,2011,60（3）：313-326.
[13] Cohen B,Novick D,Rubinstein M.Modulation of insulin activities by leptin. Science,1996,274（5290）：1185-1188.
[14] Ikejima K,Honda H,Yoshikawa M,et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology,2001,34（2）：288-297.
[15] Canbakan B,Tahan V,Balci H,et al. Leptin in nonalcoholic fatty liver disease. Ann Hepatol,2008,7（3）：249-254.
[16] Javor ED,Ghany MG,Cochran EK,et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology,2005,41（4）：753-760.
[17] Reitman ML. Leptin in the liver： a toxic or beneficial mix?. Cell Metab,2012,16（1）：1-2.
[18] Ghosh S,Singh AK,Aruna B,et al. The genomic organization of mouse resistin reveals major differences from the human resistin： functional implications. Gene,2003,305（1）：27-34.
[19] Muse ED,Obici S,Bhanot S,et al. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest,2004,114（2）： 232-239.
[20] Singhal NS,Patel RT,Qi Y,et al. Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice. Am J Physiol Endocrinol Metab,2008,295（2）：331-338.
[21] Fu Y,Luo L,Luo N,et al. Proinflammatory cytokine production and insulin sensitivity regulated by overexpression of resistin in 3T3-L1 adipocytes. Nutr Metab （Lond）,2006,3（1）：28-37.
[22] 杨云鹏,管小琴,祁明美,等. 抵抗素对NAFLD肝纤维化的影响及可能的体内外机制. 动物学研究,2012,33（4）：367-372.
[23] Zhou L,Yu X,Meng Q,et al. Resistin reduces mitochondria and induces hepatic steatosis in mice by the protein kinase C/protein kinase G/p65/PPAR gamma coactivator 1 alpha pathway. Hepatology,2013,57（4）：1384-1393.
[24] Sheng CH,Di J,Jin Y,et al. Resistin is expressed in human hepatocytes and induces insulin resistance. Endocrine,2008,33（2）：135-143.
[25] Pagano C,Soardo G,Pilon C,et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab,2006,91（3）：1081-1086.
[26] Perseghin G,Lattuada G,De Cobelli F,et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab,2006, 91（12）：5122-5125.
[27] Szalowska E,Elferink MG,Hoek A,et al. Resistin is more abundant in liver than adipose tissue and is not up-regulated by lipopolysaccharide. J Clin Endocrinol Metab,2009,94（8）：3051-3057.
[28] Rizzo G,Disante M,Mencarelli A,et al. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol,2006,70（4）：1164-1173.
[29] Abdelkarim M,Caron S,Duhem C,et al. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem, 2010,285（47）：36759-36767.
[30] Liang CP,Tall AR. Transcriptional profiling reveals global defects in energy metabolism,lipoprotein,and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem,2001,276（52）：49066-49076.
[31] Vanpatten S,Karkanias GB,Rossetti L,et al. Intracerebroventricular leptin regulates hepatic cholesterol metabolism. Biochem J,2004,379（2）：229-233.

Bile acid nuclear receptors and adipokines in the pathogenesis of non-alcoholic fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[2]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[3]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[4]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.
[5]	Xie Xiao, Lu Lungen. Noninvasive diagnosis and assessment of patients with nonalcoholic steatohepatitis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 301-306.
[6]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[7]	Huang Jiaofeng, Lin Su, Wang Mingfang, et al.. Impact of entecavir therapy on hepatic steatosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 863-867.
[8]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[9]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[10]	Yan Chenli, Wang Jingjing, Wang Jun.. Severity of coronary artery lesions and risk factors in patients with nonalcoholic fatty liver disease complicated by coronary heart disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 737-740.
[11]	Bing Hao, Li Yiling.. Correlation between non-alcoholic fatty liver disease and hepatocellular carcinoma:Fact or fiction [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 821-824.
[12]	Wang Xinwei, Lyu Ke, Sun Xiao, et al. Effect of selective β3-adrenergic receptor agonist on hepatic oxidative stress and liver fibrosis in rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 384-387.
[13]	Li Caihong, Lian Lingling, Lu Derong. Preliminary trial of ezetimibe combined with atorvastatin in treatment of patient with nonalcoholic fatty liver disease complicated by coronary heart disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 405-408.
[14]	He Xiaoping, Ran Dongmei, Qing Ling. Improved compliance of life style in patients with nonalcoholic fatty liver disease by family visit based on cross-theretical model of change [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 465-466.
[15]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.